Multimodality approaches for rectal cancer

Gary Yang, Timothy D. Wagner, Charles Thomas

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Since the NIH Consensus Conference in 1990, surgical, radiation, and chemotherapeutic advances have helped to improve local control and overall survival for patients with stage II/III rectal cancer. Based on the results of the recently completed German trial, patients with T3 and/or N1 to 2 rectal cancer should receive preoperative combined modality therapy, and undergo TME with adequate nodal dissection. This sequence of treatment allows for the better local control and sphincter preservation while optimizing survival. In addition, the toxicity profile compares favorably to intensive short course radiation or postoperative CMT. As we look toward the future, evaluation of molecular markers and treatment with targeted therapies offer the opportunity to tailor treatments to individuals to maximize the therapeutic gain.

Original languageEnglish (US)
Pages (from-to)316-342
Number of pages27
JournalCurrent Problems in Cancer
Volume28
Issue number6
DOIs
StatePublished - Nov 2004
Externally publishedYes

Fingerprint

Rectal Neoplasms
Radiation
Therapeutics
Combined Modality Therapy
Survival
Dissection

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Multimodality approaches for rectal cancer. / Yang, Gary; Wagner, Timothy D.; Thomas, Charles.

In: Current Problems in Cancer, Vol. 28, No. 6, 11.2004, p. 316-342.

Research output: Contribution to journalArticle

Yang, Gary ; Wagner, Timothy D. ; Thomas, Charles. / Multimodality approaches for rectal cancer. In: Current Problems in Cancer. 2004 ; Vol. 28, No. 6. pp. 316-342.
@article{b0e056da7491407389e884097a2af83f,
title = "Multimodality approaches for rectal cancer",
abstract = "Since the NIH Consensus Conference in 1990, surgical, radiation, and chemotherapeutic advances have helped to improve local control and overall survival for patients with stage II/III rectal cancer. Based on the results of the recently completed German trial, patients with T3 and/or N1 to 2 rectal cancer should receive preoperative combined modality therapy, and undergo TME with adequate nodal dissection. This sequence of treatment allows for the better local control and sphincter preservation while optimizing survival. In addition, the toxicity profile compares favorably to intensive short course radiation or postoperative CMT. As we look toward the future, evaluation of molecular markers and treatment with targeted therapies offer the opportunity to tailor treatments to individuals to maximize the therapeutic gain.",
author = "Gary Yang and Wagner, {Timothy D.} and Charles Thomas",
year = "2004",
month = "11",
doi = "10.1016/j.currproblcancer.2004.09.001",
language = "English (US)",
volume = "28",
pages = "316--342",
journal = "Current Problems in Cancer",
issn = "0147-0272",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Multimodality approaches for rectal cancer

AU - Yang, Gary

AU - Wagner, Timothy D.

AU - Thomas, Charles

PY - 2004/11

Y1 - 2004/11

N2 - Since the NIH Consensus Conference in 1990, surgical, radiation, and chemotherapeutic advances have helped to improve local control and overall survival for patients with stage II/III rectal cancer. Based on the results of the recently completed German trial, patients with T3 and/or N1 to 2 rectal cancer should receive preoperative combined modality therapy, and undergo TME with adequate nodal dissection. This sequence of treatment allows for the better local control and sphincter preservation while optimizing survival. In addition, the toxicity profile compares favorably to intensive short course radiation or postoperative CMT. As we look toward the future, evaluation of molecular markers and treatment with targeted therapies offer the opportunity to tailor treatments to individuals to maximize the therapeutic gain.

AB - Since the NIH Consensus Conference in 1990, surgical, radiation, and chemotherapeutic advances have helped to improve local control and overall survival for patients with stage II/III rectal cancer. Based on the results of the recently completed German trial, patients with T3 and/or N1 to 2 rectal cancer should receive preoperative combined modality therapy, and undergo TME with adequate nodal dissection. This sequence of treatment allows for the better local control and sphincter preservation while optimizing survival. In addition, the toxicity profile compares favorably to intensive short course radiation or postoperative CMT. As we look toward the future, evaluation of molecular markers and treatment with targeted therapies offer the opportunity to tailor treatments to individuals to maximize the therapeutic gain.

UR - http://www.scopus.com/inward/record.url?scp=9444288088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9444288088&partnerID=8YFLogxK

U2 - 10.1016/j.currproblcancer.2004.09.001

DO - 10.1016/j.currproblcancer.2004.09.001

M3 - Article

C2 - 15570567

AN - SCOPUS:9444288088

VL - 28

SP - 316

EP - 342

JO - Current Problems in Cancer

JF - Current Problems in Cancer

SN - 0147-0272

IS - 6

ER -